| Date | Title | Description |
| 12.08.2026 | Vaderis Therapeutics Secures $152M to Advance HHT Treatment | Vaderis Therapeutics secured $152 million in Series B funding. This landmark investment propels engasertib, a potential first treatment for rare Hereditary Hemorrhagic Telangiectasia (HHT), into global Phase 3 trials. HHT causes severe nose... |
| 11.08.2026 | Vaderis Therapeutics Raises $152M in Series B Funding | Vaderis Therapeutics, a Basel, Switzerland-based provider of targeted therapies for rare vascular diseases, raised $152M in Series B funding.
The round was led by Life Sciences at Goldman Sachs Alternatives and TCGX with participation from ... |
| 11.08.2026 | Vaderis Therapeutics closes USD 152 million Series B Financing |
Together, Vaderis Therapeutics' two milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically d... |
| 11.08.2026 | Venture Capital & Startup Funding Roundup, August 11, 2026: Bessemer Venture Partners, Citi, Sequoia Capital, Thiel Capital & More | The big picture from today’s activity: investors are pouring money into industry-specific AI and hardware-infused sectors. We see a surge of capital into defense and aerospace startups (for example, drone-maker Neros and air-taxi maker Vert... |
| 11.08.2026 | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing
Tue, Aug 11, 2026 13:00 CET Report this content
EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company'... |
| 06.05.2026 | Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology Pipeline | Windward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, S... |
| 05.05.2026 | Windward Bio secures USD 165 million to advance clinical trials |
WIN378, Windward's lead program, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression ... |
| 03.03.2026 | Alveus Therapeutics: $197 Million Series A Raised To Advance Next-Generation Obesity And Metabolic Disease Therapies | Alveus Therapeutics announced the second and final closing of its oversubscribed Series A financing, increasing the total round size to $197 million. The clinical-stage biotechnology company, which is developing next-generation therapies fo... |
| 02.03.2026 | Alveus Therapeutics Raises $37M in Series A Extension Funding | Alveus Therapeutics Inc., a Philadelphia, PA-based clinical-stage biotechnology company, raised $37M in Series A Extension funding.
The latest round included participation from Jeito Capital and Novo Holdings, joining the original Series A ... |
| 04.02.2026 | Third Arc Bio Raises $52M in Series A Extension Funding | Third Arc Bio, a Spring House, PA-based clinical stage biotechnology company, raised $52M in Series A funding.
The round was led by Andreessen Horowitz (a16z), with participation from existing investors. As part of the financing, a16z Gener... |
| 01.02.2026 | Focus on biopharma comes at the right time: Industry | - |
| 14.01.2026 | Caldera Therapeutics Launches With $112.5 Million And Doses First Subjects In Phase 1 Trial Of CLD-423 | Caldera Therapeutics, a clinical-stage biotechnology company developing a first-in-class bispecific antibody for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, launched with $112.5 million in total capital... |
| 14.01.2026 | Caldera Therapeutics Launches with $112.5M in Total Capital | Caldera Therapeutics, Inc., a Cambridge, MA-based clinical stage biotechnology company, launched with $112.5M total capital raised.
The amount consisted of a $75M Series A round from Atlas Venture, LAV and venBio, and most recently a $37.5M... |
| 13.01.2026 | Alveus Therapeutics Secures $160M Series A for Obesity, Metabolic Disease Innovation | Alveus Therapeutics, a Philadelphia-based biotech company, raised $160M in Series A funding. This significant capital infusion targets advanced therapies for obesity and metabolic diseases. New Rhein, Andera Partners, and Omega Funds led th... |
| 13.01.2026 | Spiro Medical Secures $67M to Revolutionize Asthma Treatment with PNM System | Spiro Medical secured $67 million in Series A funding. This capital fuels development of its innovative Pulmonary Neuromodulation System (PNM). PNM offers a novel, drug-free approach for severe asthma. It uses mild electrical impulses to co... |
| 08.01.2026 | Spiro Medical: $67 Million Series Raised A To Develop Neuromodulation System For Asthma | Spiro Medical, a newly formed company focused on pulmonary neuromodulation for asthma, has closed a $67 million Series A equity financing to develop what it describes as a first-of-its-kind Pulmonary Neuromodulation System (PNM) for the tre... |
| 08.01.2026 | Alveus Therapeutics Raises $160M in Series A Financing | Alveus Therapeutics, a Philadelphia, PA-based clinical-stage biotechnology company, raised $160M in Series A funding.
The round was led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi Capi... |
| 07.01.2026 | Spiro Medical Raises $67M in Series A Funding | Spiro Medical, an Irvine, CA-based medtech company developing a pulmonary neuromodulation system (PNM) for the treatment of asthma, raised $67M in Series A funding.
The round included a syndicate of venture investors led by Andera Partners ... |
| 01.12.2025 | Protego Biopharma: $130 Million Series B Funding Closed To Advance Pivotal AL Amyloidosis Program | Protego Biopharma has closed an oversubscribed $130 million Series B financing round that will accelerate its first-in-class AL amyloidosis therapeutic program into a pivotal clinical study. The round was led by Novartis Venture Fund and Fo... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing.
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 08.09.2025 | NRG Therapeutics Secures £50M to Advance Neurodegenerative Disease Therapies | NRG Therapeutics just closed a monumental £50 million Series B financing. This oversubscribed round fuels vital neurodegenerative disease research. The UK-based firm targets mitochondrial dysfunction. Its lead program, NRG5051, aims to trea... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND |
Stevenage, UK, 8 September 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B ... |
| 08.09.2025 | NRG Therapeutics Raises £50M Series B Financing | NRG Therapeutics, a Stevenage, UK-based neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, raised £50M in Series B funding.
The round was led by Health Investors’ Dementia Discovery Fund, alongside other ... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND | Stevenage, UK, 8 September 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B f... |
| 08.09.2025 | NRG Therapeutics secures £50M Series B to advance mitochondrial drugs for ALS and Parkinson’s | Stevenage-based biotech startup NRG Therapeutics has closed a £50 million Series B funding round as it moves towards clinical trials for its pipeline of treatments targeting mitochondrial dysfunction in neurodegenerative diseases.
The round... |
| 07.08.2025 | Artbio Secures $132M to Accelerate Precision Cancer Therapies | Artbio, a pioneering radiopharmaceutical firm, locked in $132 million Series B funding. This investment drives AB001, its innovative alpha radioligand therapy for metastatic castration-resistant prostate cancer, toward Phase II clinical tri... |
| 29.07.2025 | ARTBIO Raises $132M in Series B Financing | ARTBIO, a Cambridge, MA-based clinical-stage radiopharmaceutical company, raised $132M in Series B funding.
The round was led by Sofinnova Investments and B Capital, along with an existing investor and participation from F-Prime, Omega Fund... |
| 22.07.2025 | Omega Funds: $647 Million Fund VIII Closed To Invest In Life Science Companies | Global healthcare venture capital firm Omega Funds has closed its eighth fund at $647 million, surpassing its initial target of $600 million. The oversubscribed Omega Fund VIII, L.P., received backing from both new and existing investors. I... |
| 21.07.2025 | Omega Funds raises $647m for eighth fund | - |
| 03.05.2025 | Zucara Therapeutics Secures $25 Million to Combat Diabetes Complications | Zucara Therapeutics is on a mission. The Toronto-based company is tackling a significant challenge in diabetes management: hypoglycemia. Recently, Zucara completed its Series B financing, raising a total of $25 million. This funding is a li... |
| 02.05.2025 | Zucara Therapeutics: $25 Million Series B Closed For Diabetes Life Sciences Platform | Zucara Therapeutics – a diabetes life sciences company developing ZT-01, which is the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes – announced that it has completed the second and f... |
| 21.01.2025 | Alleviant Medical: $90 Million Raised For Developing No-Implant Atrial Shunt For Heart Failure | Alleviant Medical – a privately held medical device company developing a no-implant atrial shunt for heart failure – announced a $90 million financing to fund its second pivotal trial. The round was led by Gilde Healthcare, and it also incl... |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| 13.01.2025 | Windward Bio launches with $200 million Series A financing round |
Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
| 07.01.2025 | Aviceda raises $207M series C to take geographic atrophy drug through phase 3 | Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug.
The round was co-led by the healthcare funds Omega Funds and TCGX, wi... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 12.12.2024 | Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M | Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector.
Concurrent with the merger, nChr... |
| 30.07.2024 | Kestra Medical and T. Rowe Price: Pioneering Innovations in Healthcare and Sustainable Finance | In the ever-evolving landscape of healthcare and finance, two companies are making waves. Kestra Medical Technologies is redefining cardiac care with its innovative wearable devices. Meanwhile, T. Rowe Price is spearheading sustainable inve... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 29.07.2024 | Kestra Medical: Wearable Cardioverter Defibrillator Company Closes $196 Million In Funding | Kestra Medical Technologies (a privately held wearable medical device and digital healthcare company) announced an oversubscribed $196 million funding round to support the expansion of their commercial organization and advance its goals of ... |
| 28.07.2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
| 27.07.2024 | CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series D | CatalYm announced the completion of a $150 million Series D financing. The oversubscribed funding round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge**
** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
| 23.07.2024 | Third Arc Bio launches with $165M to address unmet needs in oncology and autoimmunity | The company was founded by executives from Johnson & Johnson
Third Arc Bio is a company that says its on mission to deliver transformational therapies for solid tumors and inflammatory & immunology diseases through the use of multif... |
| 23.07.2024 | Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases | -- Company formed and originally seeded by Omega Funds, Series A financing with exceptional syndicate led by Vida Ventures
-- World-class leadership team led by Peter F. Lebowitz, MD, PhD, Sanjaya Singh, PhD, and Joe Erhardt, PhD, well-posi... |
| 06.10.2023 | Aerium Therapeutics begins development of three in-licensed antibodies | |
| 12.01.2023 | Andera Partners backs $60 million series C for hypertension medtech SoniVie | SoniVie, an Italy and Israel-run med tech seeking to treat hypertension through the use of ultrasound, has closed a $60 million series C round to make headway toward its clinical and regulatory pipeline.
Paris-based Andera Partners led the ... |
| 09.01.2023 | SoniVie Raises $60m in Round C Financing, and Appoints New Board Members | The funds, provided by new investors and current shareholder, will be used to support the Company clinical and regulatory path towards pre-market approval of its TIVUS™ technology for the treatment of hypertension
TEL AVIV, Israel, Jan. 9, ... |
| 13.04.2022 | CDR-Life Closes $76 million Series A Funding | |
| 20.12.2021 | Omega Funds Closes Fund VII, at $650M | Omega Funds, a Boston, MA-based international healthcare venture capital firm focused on delivering impactful medicines to patients, closed its seventh fund with $650m in limited partner capital commitments.
The new fund, Omega Fund VII, L.... |
| 17.12.2021 | Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies | BOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million i... |
| 14.10.2021 | Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund | Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A... |
| 16.09.2021 | Anjarium Biosciences Raises CHF 55.5 Million Series A Financing | |
| 14.09.2021 | Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases | – Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies –
– Lead program targets Parkinson’s disease and all forms of Gaucher disease –
C... |
| 27.07.2021 | Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X | • Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios’ DDR-based platform... |
| 27.07.2021 | IP : Artios Pharma Ltd - Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X | • Funding propels Artios' ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios' DDR-based platform... |
| 05.01.2021 | Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds | BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc., a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B... |
| 05.01.2021 | Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds | Ikena Oncology, Inc. (“Ikena”), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing. The... |
| 05.01.2021 | Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds | - |
| 16.10.2020 | Chord Therapeutics launches with USD 16 million Series A financing | |
| 16.10.2020 | Chord Therapeutics launches with USD 16 million Series A financing | Chord Therapeutics, a clinical stage biopharmaceutical company developing drugs for rare diseases, today announces the closing of a USD16 million Series A financing exclusively from leading healthcare investor Omega Funds. In conjunction wi... |
| 20.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | - |
| 19.02.2020 | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | – Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indications
– Existing Investors Novo Holdings and RiverVest Venture Partners support the deal with new Investors HealthCap, Rock Springs Capital... |
| 11.12.2019 | Omega Funds Secures $438M for Sixth Fund to Invest in the Future of Medicine | Omega Funds, a Boston, MA-based investment firm focused on backing companies delivering impactful medicines to patients, closed Omega Fund VI, L.P., with $438 million in capital commitments.
With Fund VI, the firm will continue to execute o... |
| 28.10.2019 | Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds | Nuvation Bio, Inc., a stealth biotechnology company developing proprietary therapies focused on oncology, announces the closing of $275 million in an oversubscribed Series A financing. The round was led, structured and syndicated by Omega F... |
| 22.05.2017 | Anaconda Biomed Secures 15M Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds | Anaconda Biomed, a pre-clinical stage medical device company focused on the development of the next generation of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announces it has closed a Series A financin... |
| - | Wow of the week: 3-D scanner maps ear canal to improve hearing aid development (video) | In a move to disrupt the hearing industry, a medical device company has launched a handheld 3-D scanner to map the inner ear to improve the quality of hearing aids. It’s also offering the platform to any hearing aid maker that wants it.
The... |
| - | Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth | – Proceeds to advance development of Tildacerfont in Congenital Adrenal Hyperplasia and other indications
– Existing Investors Novo Holdings and RiverVest Venture Partners support the deal with new Investors HealthCap Partners, Rock Spring... |
